The anti-factor Xa range for low molecular weight heparin thromboprophylaxis

Salena May Ward, Matthew Yuankun Wei

Research output: Contribution to journalArticleOtherpeer-review

Abstract

Low molecular weight heparins (LMWHs) are now the mainstay option in the prevention and treatment of venous thromboembolism. In some patients receiving therapeutic doses of LMWH, activity can be measured by quantifying
the presence of Anti-factor Xa (AFXa) for dose adjustment. However, currently there are no guidelines for LMWH monitoring in patients on thromboprophylactic, doses, despite certain patient populations may be at risk of suboptimal dosing. This review found that while the AFXa ranges for therapeutic levels of LMWHs are relatively well defined in the literature, prophylactic ranges are much less clear, thus making it difficult to interpret current research data. From the studies published to date, we concluded that a reasonable AFXa target range for LMWH deep venous thromboses prophylaxis might be 0.2-0.5 IU/mL.
Original languageEnglish
Article number5844
Pages (from-to)80-83
Number of pages4
JournalHematology Reports
Volume7
Issue number4
DOIs
Publication statusPublished - 23 Nov 2015

Cite this

@article{d91780e339bc4300a533adfc616a90c0,
title = "The anti-factor Xa range for low molecular weight heparin thromboprophylaxis",
abstract = "Low molecular weight heparins (LMWHs) are now the mainstay option in the prevention and treatment of venous thromboembolism. In some patients receiving therapeutic doses of LMWH, activity can be measured by quantifyingthe presence of Anti-factor Xa (AFXa) for dose adjustment. However, currently there are no guidelines for LMWH monitoring in patients on thromboprophylactic, doses, despite certain patient populations may be at risk of suboptimal dosing. This review found that while the AFXa ranges for therapeutic levels of LMWHs are relatively well defined in the literature, prophylactic ranges are much less clear, thus making it difficult to interpret current research data. From the studies published to date, we concluded that a reasonable AFXa target range for LMWH deep venous thromboses prophylaxis might be 0.2-0.5 IU/mL.",
author = "Ward, {Salena May} and Wei, {Matthew Yuankun}",
year = "2015",
month = "11",
day = "23",
doi = "10.4081/hr.2015.5844",
language = "English",
volume = "7",
pages = "80--83",
journal = "Hematology Reports",
issn = "2038-8322",
publisher = "PAGEpress",
number = "4",

}

The anti-factor Xa range for low molecular weight heparin thromboprophylaxis. / Ward, Salena May; Wei, Matthew Yuankun.

In: Hematology Reports, Vol. 7, No. 4, 5844, 23.11.2015, p. 80-83.

Research output: Contribution to journalArticleOtherpeer-review

TY - JOUR

T1 - The anti-factor Xa range for low molecular weight heparin thromboprophylaxis

AU - Ward, Salena May

AU - Wei, Matthew Yuankun

PY - 2015/11/23

Y1 - 2015/11/23

N2 - Low molecular weight heparins (LMWHs) are now the mainstay option in the prevention and treatment of venous thromboembolism. In some patients receiving therapeutic doses of LMWH, activity can be measured by quantifyingthe presence of Anti-factor Xa (AFXa) for dose adjustment. However, currently there are no guidelines for LMWH monitoring in patients on thromboprophylactic, doses, despite certain patient populations may be at risk of suboptimal dosing. This review found that while the AFXa ranges for therapeutic levels of LMWHs are relatively well defined in the literature, prophylactic ranges are much less clear, thus making it difficult to interpret current research data. From the studies published to date, we concluded that a reasonable AFXa target range for LMWH deep venous thromboses prophylaxis might be 0.2-0.5 IU/mL.

AB - Low molecular weight heparins (LMWHs) are now the mainstay option in the prevention and treatment of venous thromboembolism. In some patients receiving therapeutic doses of LMWH, activity can be measured by quantifyingthe presence of Anti-factor Xa (AFXa) for dose adjustment. However, currently there are no guidelines for LMWH monitoring in patients on thromboprophylactic, doses, despite certain patient populations may be at risk of suboptimal dosing. This review found that while the AFXa ranges for therapeutic levels of LMWHs are relatively well defined in the literature, prophylactic ranges are much less clear, thus making it difficult to interpret current research data. From the studies published to date, we concluded that a reasonable AFXa target range for LMWH deep venous thromboses prophylaxis might be 0.2-0.5 IU/mL.

UR - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691677/pdf/hr-2015-4-5844.pdf

U2 - 10.4081/hr.2015.5844

DO - 10.4081/hr.2015.5844

M3 - Article

VL - 7

SP - 80

EP - 83

JO - Hematology Reports

JF - Hematology Reports

SN - 2038-8322

IS - 4

M1 - 5844

ER -